[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561868":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":20,"collaborators":7,"id":24,"slug":25,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":29,"acronym":7,"eligibilityCriteria":30,"healthyVolunteers":26,"sex":31,"minAge":32,"maxAge":33,"enrollmentInfo":34,"targetDuration":7,"studyType":37,"phases":7,"briefSummary":38,"conditions":39,"keywords":41,"overallStatus":51,"whyStopped":7,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},{"fullName":5,"class":6},"Menoufia University","OTHER",null,[9],{"facility":10,"status":7,"city":11,"state":7,"zip":7,"country":12,"countryCode":13,"cosmosGeoPoint":14,"geoPoint":19,"contacts":7},"Menofia university","Shibīn al Kawm","Egypt","EG",{"type":15,"coordinates":16},"Point",[17,18],31.00904,30.55258,{"lat":18,"lon":17},{"type":21,"investigatorFullName":22,"investigatorTitle":23,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Naglaa Fathy Mohamed Ebaid","Assistant Lecturer of clinical pharmacy","100561868","this-study-investigates-the-impact-of-single-nucleotide-polymorphisms-in-genes-involved-in-the-pharmacokinetics-and-toxicity-of-doxorubicin-dox-in-egyptian-female-patients-with-breast-cancer-it-also-aims-to-explore-the-association-of-pretreatment-neutrophil-to-lymphocyte-ratio-to-pcr-100561868",false,"NCT06595758","This Study Investigates the Impact of Single Nucleotide Polymorphisms in Genes Involved in the Pharmacokinetics and Toxicity of Doxorubicin (DOX) in Egyptian Female Patients with Breast Cancer. It Also Aims to Explore the Association of Pretreatment Neutrophil to Lymphocyte Ratio to PCR","Effects of Pharmacogenetics on Pharmacokinetics and Toxicity of Doxorubicin in Egyptian Breast Cancer Patients","Inclusion Criteria:\n\n* Females aged ≥ 18 years\n* Performance status 0 or 1\n* No contraindication to chemotherapy\n* Adequate bone marrow\n* Adequate hepatic function\n* Adequate renal function\n\nExclusion Criteria:\n\n* Poorly controlled diabetes mellitus\n* Ischemic heart disease\n* Uncontrolled hypertension\n* Active infections\n* Baseline ejection fraction \\< 50%\n* Performance status ≥ 2\n* Pregnancy Lactation, bilateral breast cancer, male patients, primary surgery, distant metastases, other malignancies, inflammations, hematological disorders, autoimmune diseases, and patients taking non-steroidal anti-inflammatory drugs (NSAIDs), steroidal and antibiotic therapy.","FEMALE","18 Years","75 Years",{"count":35,"type":36},100,"ACTUAL","OBSERVATIONAL","This study aims to investigate the effect of single nucleotide polymorphisms (SNPs) of genes involved in doxorubicin transport and metabolism on its pharmacokinetics and toxicity in Egyptian breast cancer patients.\n\nIt also aims to explore the association of pretreatment neutrophil to lymphocyte ratio (NLR) with pathological complete response (pCR).",[40],"Breast Cancer",[42,43,44,45,46,47,48,49,50],"Doxorobicin","Pharmacokinetics","SLC22A16","CBR1","SNPs","Toxicity","Neoadjuvant chemotherapy","Pathological complete response","Neutrophil to lymphocyte ratio","COMPLETED","2024-09-11",{"date":54,"type":36},"2024-09-19",{"date":56,"type":36},"2021-10-01",{"date":58,"type":36},"2023-11-01",{"name":5,"class":6},1]